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Summary Central nervous system involvement is a serious complication of brucellosis; data
found in the literature are generally restricted to case reports and case series. In this study we
pooled the data from Turkish medical practice in order to gain a thorough understanding of the
subject. A search of Turkish publications on chronic neurobrucellosis was made using both Turkish
and international databases. A total of 35 publications were analyzed and 187 neurobrucellosis
cases were evaluated. Headache, fever, sweating, weight loss, and back pain were the pre-
dominant symptoms, while meningeal irritation, confusion, hepatomegaly, hypoesthesia, and
splenomegaly were the most frequent findings. The major complications in patients were cranial
nerve involvement, polyneuropathy/radiculopathy, depression, paraplegia, stroke, and abscess
formation. Antibiotics were used in different combinations and over different intervals. The
duration of antibiotic therapy reported ranged from 2 to 15 months (median 5 months). The
mortality was 0.5% with suitable antibiotics. Neurobrucellosis maymimic various pathologies. For
this reason, a thorough evaluation of the patient with probable disease is crucial for an accurate
diagnosis and proper management of the disease.
# 2009 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.Introduction
Brucellosis is the most common zoonotic infection in the
world. More than 500 000 new cases occur annually, but with
an uneven global distribution.1 Although brucellosis can be
found worldwide, it is more common in countries that do not
have good standardized and effective public health and
domestic animal health programs. Areas currently listed
as high risk are the Mediterranean Basin (Portugal, Spain,* Corresponding author. Tel.: +90 532 7842024.
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doi:10.1016/j.ijid.2009.02.015Southern France, Italy, Greece, Turkey, North Africa), South
and Central America, Eastern Europe, Asia, Africa, the
Caribbean, and the Middle East.2 Turkey, with a population
of 72 million, is a large country located in the East Medi-
terranean Basin. According to data from the Turkish Ministry
of Health on the overall hospitalizations throughout the
country in 2004, 6793 brucellosis cases were hospitalized
with a resultant 0.3% mortality.3
The organism was first identified in 1887 by Bruce, from
autopsy material of a patient who died on the island of Malta;
neurobrucellosis was first reported by Hughes in 1896. Cen-
tral nervous system (CNS) involvement is a serious complica-
tion of brucellosis and the clinical presentation is quiteational Society for Infectious Diseases.
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problem throughout the world and particularly in the Med-
iterranean Basin. Various discrepancies in the diagnosis and
management of the disease still exist, and data in the
literature are generally restricted to case reports and series.
In this study we pooled the data from Turkish medical prac-
tice for 187 cases in order to gain a thorough understanding of
neurobrucellosis.
Patients and methods
The clinical and microbiological diagnostic properties of
chronic neurobrucellosis patients were evaluated in this
review. Turkish publications associated with neurobrucellosis
were searched through both Turkish (Ulakbim and Pleksus) and
international (Medline) databases. Presentations in national
Turkish congress books related with both microbiology and
infectious diseases were also considered. We included papers
published since 1998, hence covering a 10-year period. The
inclusion criteria for the publications were those diagnosing
neurobrucellosis with the existence of a neurological picture
not explained by any other neurological disease, evidenced by
positive culture or serological tests either in blood or in
cerebrospinal fluid (CSF), and the presence of inflammatory
alteration in theCSF. If one of either theRoseBengal test or the
Wright agglutination test was positive, then the patient was
accepted to be seropositive.
Limitations of the study
Patient gender was not detailed in some of the publications.
Also, the retrospective analyses could not discriminate
between those studies with negative laboratory results and
those where tests were not used. For this reason the diag-
nostic data given only represent the positive results. Further,
antibiotics were used in different combinations and forTable 1 Clinical presentation in 187 neurobrucellosis cases
Complaints on admission Physical findin
Headache (57%) Meningeal irrit
Fever (57%) Confusion (18%
Sweating (30%) Hepatomegaly
Weight loss (28%) Hypoesthesia (
Back pain (23%) Splenomegaly
Walking difficulty (17%) Convulsions (8
Nausea and vomiting (17%) Hemiparesis (4
Weakness in the extremities (15%) Paraplegia (4%
Sensory loss in the extremities (13%) Dysarthria (4%
Hearing loss (10%) Diplopia (4%)
Blurred vision (6%) Papilledema (3
Urinary incontinence (4%) Coma (3%)
Double vision (4%) Ataxia (1%)
Memory deficit (2%) Pancreatitis (0
Amenorrhea (3 cases) a
Fecal incontinence (0.5%)
a The proportion of females is not delineated in the publications, hedifferent durations, hence therapeutic comparisons were
confounded. As a consequence we could not compare the
efficacy of the therapeutic regimens used.
Results
A total of 35 publications were analyzed in our study:4—38 17
case reports, 11 case series, and seven original articles. All of
the original articles evaluated systemic brucellosis in its
entirety, and the data related with neurobrucellosis were
extracted for our review. The clinical findings of 186 cases
derived from Turkish publications and one additional case
treated in our department, giving a total of 187 cases, were
considered in this paper. The average age of the cases was
40.3 years (range 10—77 years). Gender was reported for 119
patients — there were 68 males and 51 females.
Headache, fever, sweating, weight loss, and back painwere
the predominant symptoms, while meningeal irritation, con-
fusion, hepatomegaly, hypoesthesia, and splenomegaly were
themostfrequentfindings.Themajorcomplications inpatients
were cranial nerve (CN) involvement, polyneuropathy/radicu-
lopathy,depression,paraplegia,stroke,andabscessformation.
Clinical presentations of the cases are shown in Table 1 and the
results of diagnostic tests are shown in Table 2.
The duration of antibiotic therapy was reported for 56
patients in the publications (2—15 months; median 5
months). Ceftriaxone, doxycycline, rifampin, trimetho-
prim—sulfamethoxazole, streptomycin, gentamicin, and
ofloxacin were the drugs used in different combinations
and over different intervals.
Discussion
Nervous system involvement in brucellosis might be due to the
persisting intracellular microorganism, or perhaps the infec-
tion triggers an immune mechanism leading to neuropathol-gs Complications
ation (37%) Cranial nerve involvement (19%)
) 8th CN, 19 cases
(15%) 6th CN, 14 cases
12%) 7th CN, 3 cases
(11%) Polyneuropathy/radiculopathy (7%)
%) Depression (5%)
.5%) Paraplegia (4%)
) Stroke (3.2%)
) Subarachnoid hemorrhage, 1 case
Subdural hematoma, 1 case
%) Ischemia, 4 cases
CNS abscesses (3%)
Brain abscess, 3 cases
.5%) Spinal cord abscess, 1 case
Epidural abscess, 1 case
Cerebellar abscess, 1 case
Hydrocephalus (1.5%)
Intracranial hypertension (0.5%)
Death (0.5%)
nce the exact frequency of amenorrhea cannot be given.
Table 2 Laboratory diagnoses in 187 neurobrucellosis cases
Blood analyses CSF analyses Serum plus CSF positivity
Rose Bengal test 55 (29%) 39 (21%) 25 (13%)
Tube agglutination test 152 (81%) 133 (71%) 113 (60%)
Culture 52 (28%) 27 (14%) 15 (8%)
CSF, cerebrospinal fluid.
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molecules expressed on the surface of Brucella melitensis
were found to induce anti-GM1 ganglioside antibodies, result-
ing in flaccid limb weakness and ataxia-like symptoms.39 It is
generally understood that there are three categories of neu-
rological involvement in brucellosis: meningoencephalitis,
polyradiculoneuropathy, and diffuse involvement.1,40 Theper-
ipheral form, that of polyradiculoneuropathy, was found to
occur in around 7% of our cases. The central form is diffuse CNS
involvement, predominantly with myelitis or cerebellar invol-
vement. Although the two chronic forms, peripheral and
central, are distinct, some overlapping may be possible.40
Clinical studies have shown that fever is the most common
feature of systemic brucellosis, followed by osteoarticular
involvement, sweating, and constitutional symptoms.41 In
our neurobrucellosis cases, fever, headache, sweating, and
weight loss were the predominant complaints, followed by
neurological symptoms. On physical examination the findings
of meningeal irritation were seen in only one third of the
cases. Other neurological presentations, like hypoesthesia,
hemiparesis, paraplegia, dysarthria, papilledema, confusion,
convulsion, and coma were seen in a diverse pattern. Con-
ventional findings like hepatomegaly and splenomegaly,
which are frequently seen in systemic brucellosis, were rare
in cases with CNS involvement. Unquestionably neurobrucel-
losis appears to be a subtle disease mimicking various pathol-
ogies and requires the utmost attention for a definite
diagnosis.
In fact, the detection of neurobrucellosis is based on the
existence of a neurological picture not explained by any
other neurological disease, evidenced by systemic brucellar
infection, and the presence of inflammatory alteration in the
CSF. Although positive culture is the gold standard for diag-
nosis, it has often been thought to be suboptimal.42,43
According to our data 28% of the patients with CNS brucellosis
had positive blood cultures and 14% of the cases had CSF
culture positivity. Unfortunately, data were lacking on the
issue of culture, as the proportion of patients for whom
culture had been applied was not clearly delineated in the
Turkish publications. That is, if culture was systematically
applied to all cases, surely the yield would be higher, and thus
the culture process should not be undertaken in probable
cases. In a significant proportion of our patients, laboratory
diagnoses were established with serological tests. These
tests are generally easy to perform and can be utilized even
in underdeveloped countries with limited resources.
The involvement of various CN as a component of neuro-
brucellosis has been reported in the literature. Brucellar CN
palsies usually resolve completely with the administration of
antibiotics, whereas those with chronic CNS infections often
have permanent neurologic deficits.4,44,45 In our patient
database, CN involvement was the most frequent complica-
tion of neurobrucellosis. One fifth of the cases presented CNinvolvement particularly at the sixth and eighth cranial
nerves. Hearing loss in brucellosis may develop following
involvement of the central auditory pathways or by avascular
neural tissue due to the reflex spasms caused by endotox-
ins.46,47 A predilection for the vestibulo-cochlear cranial
nerve (CN8), leading to sensorineural hearing loss has been
reported in case reports.40,48 Brucella species targeting CN8
and leading to hearing loss was the foremost CN involvement
in our data. The second site of CN involvement was the
abducens nerve (CN6). Abducens palsy, which is the most
common type of ocular nerve palsy in general, is due to
lateral rectus muscle paresis with the resultant horizontal
diplopia. Moreover, the abducens nerve has the longest
intracranial course and is therefore susceptible to direct
and indirect insults like microvascular infarction or direct
compression.49 Diplopia due to CN6 paralysis in CNS brucel-
losis is known to be a very rare complication.50,51 Never-
theless, 4% of the patients complained of double vision and
physical examination revealed CN6 involvement. Hence,
ophthalmic complications of neurobrucellosis are not as rare
as is expected. Finally, the involvement of the seventh CN
came in third among CN complications.
Papilledema, which may blur vision, has been reported in
neurobrucellosis.50,52,53 Both pseudotumor cerebri and papil-
litis have been implicated in the pathophysiology.52,54 Pseu-
dotumor cerebri is characterized by increased CSF pressure
and papilledema, but generally with preserved vision and
pupillary reflexes. Papillitis presents as pain on movement of
the eyes, papilledema, rapidly occurring visual loss, and
relative afferent pupillary defect. Although it was found to
be as high as 3% in our cases, 6% of the patients complained of
visual blurring. Ischemic vasculitis affecting the vasa ner-
vorum of the optic nerve and sparing of the retina may be the
probable explanation for this controversy.52
Cerebrovascular disease is one of the most common rea-
sons for neurological emergencies,55 and neurobrucellosis
mimicking cerebrovascular accidents has already been
recorded in the literature.56 Hemorrhages, transient
ischemic attacks, and venous thrombosis are meningovascu-
lar complications of neurobrucellosis.38,57 Cerebrovascular
involvement in neurobrucellosis is explained mainly by two
mechanisms.58 The first mechanism is rupture of a mycotic
aneurysm. The other mechanism is the inflammatory process
of the vessels –— particularly arteritis, with resultant lacunar
infarcts, small hemorrhages, or venous thromboses. Vascu-
litic involvement of the deep penetrating cerebral vessels has
been proposed, even though angiographic findings have been
found to be normal.53 In our cases we found cerebrovascular
disease to be as high as 3.2%, due to subarachnoid hemor-
rhage, subdural hematoma, and ischemia, and the probabil-
ity of neurobrucellosis should be considered in neurological
emergencies where brucellosis is endemic. Likewise, abscess
formation due to CNS brucellosis was not exceptional and
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inflammation within the CSF space may block CSF reuptake
by arachnoid villi, causing hydrocephalus.19 In our study,
hydrocephalus was seen in 1.5% of the cases.
Disturbances of orientation,memory, attention, and pov-
erty of content due to neurobrucellosis can be seen with
the absence of either unconsciousness or deterioration in
general status. The improvement of cognitive and mood
disorders without anti-depressive and antipsychotic treat-
ments distinguishes the disease from other functional psy-
chiatric disorders.59 Unfortunately, clinicians dealing with
neurobrucellosis generally overlook psychiatric changes
that may debilitate the patients. Accordingly, depression
was found in around 5% of our cases and this emphasizes the
need for psychiatric support when necessary. Also, anti-
epileptic medications might be necessary to control sei-
zures, which were seen in 8% of the patients in our analysis.
Cortical hyperactivity can be observed in electroencepha-
lography in these cases.
CNS involvement was not limited to cerebral or cerebellar
symptoms and myelopathy was not exceptional in Turkish
cases in whom paraplegia, urinary incontinence, ataxia, and
fecal incontinence were reported in less than 5%. Myelitis is
generally evidenced by back pain, ataxia, paresthesia, para-
plegia, and sphincter abnormalities. Recurrence of myelitis
has also been reported.60
Administration of appropriate antimicrobial therapy to all
patients in whom the diagnosis of CNS infection is suspected
is a rule.61 Similarly, two or three suitable antibiotics are
recommended for long periods in neurobrucellosis, although
therapy should be individualized.56,62 The duration of ther-
apy was reported to be around six months with suitable
antibiotics.18 Accordingly, the median duration of antibiotic
use was five months in our case series. Fortunately, neuro-
brucellosis in human beings is rarely fatal with proper man-
agement. High eradication rates can be achieved, although
the disease may be severely debilitating and disabling. Death
has been reported to be rare in the literature,51,63,64 and
occurred in 0.5% in our analysis.
Since neurobrucellosis mimics peripheral and CNS pathol-
ogies, differential diagnosis is important in probable
patients. Neuroimaging and neurophysiologic evaluation
combined with the microbiological diagnostic tools is useful
for both diagnosis and the detection of complications. In
conclusion, accurate diagnosis and proper management of
CNS brucellosis appears to be fundamental since it is a very
subtle disease.
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